TRIDENT-1
22 Dec 2020
Trial Summary
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), themaximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose(RP2D) of repotrectinib given to adult subjects with advanced solid malignant tumors.
Acronym:
TRIDENT-1
ACTRN/NCT /ethics:
NCT03093116
Scientific title:
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Sponsor / Cooperative group:
Turning Point Therapeutics
Trial & Patient Characteristics
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I; Phase II |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2017-02-27 |
| Anticipated End Date | 2022-12-31 |
Participating Hospitals
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Alison Richards |
| Alison.Richards@sa.gov.au | |
| Phone | 08 8206 4835 |
| Principal Investigator | Professor Chris Karapetis |
| Recruitment Status | Recruiting |